

PATIENT NAME : ANU DEVI

REF. DOCTOR : DR. SADAR HOSPITAL

ACCESSION NO : **0707XG000089**
 PATIENT ID : ANUDF230181707
 CLIENT PATIENT ID:
 ABHA NO :

AGE/SEX : 43 Years Female
 DRAWN : 02/07/2024 11:36:18
 RECEIVED : 02/07/2024 11:38:53
 REPORTED : 02/07/2024 18:59:03

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY - CBC

CBC WITH ESR (CBC+PS+ESR) EDTA WHOLE BLOOD/SMEAR

BLOOD COUNTS, EDTA WHOLE BLOOD

Parameter	Value	Reference Range	Units
HEMOGLOBIN (HB)	10.0 Low	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT	3.47 Low	3.8 - 4.8	mil/ μ L
WHITE BLOOD CELL (WBC) COUNT	6.10	4.0 - 10.0	thou/ μ L
PLATELET COUNT	161	150 - 410	thou/ μ L

RBC AND PLATELET INDICES

Parameter	Value	Reference Range	Units
HEMATOCRIT (PCV)	30.1 Low	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV)	87.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	28.7	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	33.1	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	15.2 High	11.6 - 14.0	%
MENTZER INDEX	25.1		
MEAN PLATELET VOLUME (MPV)	9.8	6.8 - 10.9	fL

WBC DIFFERENTIAL COUNT

Parameter	Value	Reference Range	Units
NEUTROPHILS	60	40 - 80	%
LYMPHOCYTES	34	20 - 40	%
MONOCYTES	03	2 - 10	%
EOSINOPHILS	03	1 - 6	%
BASOPHILS	0	< 1 - 2	%
ABSOLUTE NEUTROPHIL COUNT	3.66	2.0 - 7.0	thou/ μ L
ABSOLUTE LYMPHOCYTE COUNT	2.07	1.0 - 3.0	thou/ μ L
ABSOLUTE MONOCYTE COUNT	0.18 Low	0.2 - 1.0	thou/ μ L
ABSOLUTE EOSINOPHIL COUNT	0.18	0.02 - 0.50	thou/ μ L
ABSOLUTE BASOPHIL COUNT	0	0.0 - 0.1	thou/ μ L
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.8		

Sanjeev

Dr. Sanjeev Kumar
 Consultant - Pathologist &
 Laboratory Head



View Details



View Report

PERFORMED AT :

Agilus Pathlabs Reach Limited
 Sadar Hospital, Sector-1, Bokoro Steel City,
 Bokoro, 827001
 Jharkhand, India
 Tel : 7260813496
 Email : customercare.bokoro@agilus.in



ULR No. 775000008232563

PATIENT NAME : ANU DEVI

REF. DOCTOR : DR. SADAR HOSPITAL

ACCESSION NO - **0707XG000089**
 PATIENT ID - ANUDF230181707
 CLIENT PATIENT ID
 ASHA NO

AGE/SEX - 43 Years Female
 DRAWN - 02/07/2024 11:36:18
 RECEIVED - 02/07/2024 11:38:11
 REPORTED - 02/07/2024 18:59:01

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY

CBC WITH ESR (CBC+PS+ESR) EDTA WHOLE BLOOD/SMEAR

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

E.S.R **80 High** 0 - 20 mm at 1 hr

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic. It is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRF in first trimester is 0-48 mm/hr (62 if anemic) and in second trimester (0-70 mm/hr (95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs (Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACCPress, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.



Dr. Sanjeev Kumar
 Consultant - Pathologist &
 Laboratory Head



View Details

View

PERFORMED AT :

Agilus Pathlabs Reach Limited

Sadar Hospital, Sector-1, Bokaro Steel City,

Bokaro, 827001

Jharkhand, India

Tel : 7760813496

Email : customer@reach@agilus.in



ULR No. 775000008232563



PATIENT NAME : ANU DEVI

REF. DOCTOR : DR. SADAR HOSPITAL

CODE/NAME & ADDRESS : CR00000048
KIT DOWN - BOKORO
SADAR HOSPITAL,
BOKORO 827001
9971116367

ACCESSION NO : 0031XG002140
PATIENT ID : ANUDF03078131
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 43 Years Female
DRAWN : 02/07/2024 11:07:00
RECEIVED : 03/07/2024 12:43:56
REPORTED : 03/07/2024 14:37:44

CLINICAL INFORMATION :

0707XG000089

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL METHOD : DIAZONIUM SALT	0.60	0.2 - 1.2	mg/dL
BILIRUBIN, DIRECT METHOD : DIAZO REACTION	0.20	0.0 - 0.5	mg/dL
BILIRUBIN, INDIRECT METHOD : CALCULATED	0.40	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD : BIURÉT	8.2	6.0 - 8.30	g/dL
ALBUMIN METHOD : COLORIMETRIC (BROMCRESOL GREEN)	4.0	3.5 - 5.2	g/dL
GLOBULIN	4.2 High	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER	1.0	1 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : ENZYMATIC (NADH (WITHOUT P-5'-P))	15	5 - 34	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : ENZYMATIC (NADH (WITHOUT P-5'-P))	9	0 - 55	U/L
ALKALINE PHOSPHATASE METHOD : PARA-NITROPHENYL PHOSPHATE	269 High	40 - 150	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : L-GAMMA-GLUTAMYL-4-NITROANALIDE /GLYCYLGLYCINE KINETIC METHOD	41 High	8 - 33	U/L
LACTATE DEHYDROGENASE METHOD : IFCC LACTATE TO PYRUVATE	185	125 - 220	U/L

URIC ACID, SERUM

URIC ACID METHOD : URICASE	5.1	2.6 - 6.0	mg/dL
--------------------------------------	-----	-----------	-------

Interpretation(s)

LIVER FUNCTION PROFILE, SERUM-
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

Chaitali

A.Chatterjee

Page

Dr. Chaitali Ray, PHD
Chief Biochemist cum MRQA

Dr. Anwasha Chatterjee, MD, DipRCPATH
(Histopathology)
Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd
P-5 Srijan Tech Park Building, Dn-52, Unit No. 2, Ground Floor, Sector V, Salt Lake,
Kolkata, 700091
West Bengal, India
Tel : 9111591115, Fax : 30203412



ULR No.31000005051371-0031

DIAGNOSTIC REPORT

PATIENT NAME : ANU DEVI		REF. DOCTOR : DR. SADAR HOSPITAL	
ACCESSION NO : 0707XG000089	AGE/SEX : 43 Years Female	DRAWN : 02/07/2024 11:36:18	RECEIVED : 02/07/2024 11:38:51
PATIENT ID : ANUDF230181707	CLIENT PATIENT ID :	REPORTED : 02/07/2024 18:59:01	
ADHA NO :			

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY


LIVER FUNCTION PROFILE, SERUM

TOTAL PROTEIN 7.5 6.0 - 8.3 g/dL

KIDNEY FUNCTION TEST

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 49 High 6 - 22 mg/dL



CREATININE, SERUM
 CREATININE 4.80 High 0.6 - 1.2 mg/dL

Sanjeev
Dr. Sanjeev Kumar
 Consultant - Pathologist &
 Laboratory Head

Page 4 of 4

View Details


View Report

PERFORMED AT :
Agilus Pathlabs Reach Limited
 Sadar Hospital, Sector-1, Bokoro Steel City,
 Bokoro, 827001
 Jharkhand, India
 Tel : 7260813496
 Email : customercare_bokoro@agilus.in

ULR No.775000008232563-0707


PATIENT NAME : ANU DEVI		REF. DOCTOR : DR. SADAR HOSPITAL	
ACCESSION NO	0707XG000089	AGE/SEX	43 Years Female
PATIENT ID	ANUDF230181707	DRAWN	02/07/2024 11:36:18
CLIENT PATIENT ID		RECEIVED	02/07/2024 11:38:53
ABHA NO		REPORTED	02/07/2024 18:59:03

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------



BUN/CREAT RATIO			
BUN/CREAT RATIO	10.21	5.0 - 15.0	
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.5	6.0 - 8.3	g/dL
ALBUMIN, SERUM			
ALBUMIN	4.5	3.2 - 5.0	g/dL
GLOBULIN			
GLOBULIN	3	2.0 - 4.1	g/dL
CALCIUM, SERUM			
CALCIUM	8.4	8.4 - 10.4	mg/dL

Sanjeev
Dr. Sanjeev Kumar
 Consultant - Pathologist &
 Laboratory Head



PERFORMED AT :
 Agilus Pathlabs Reach Limited
 Sadar Hospital, Sector-1, Bokoro Steel City,
 Bokoro, 827001
 Jharkhand, India
 Tel : 7560813496
 Email : c.saran@reach.bokoro@agilus.in



PATIENT NAME : ANU DEVI		REF. DOCTOR : DR. SADAR HOSPITAL	
ACCESSION NO : 0707XG000089	AGE/SEX : 43 Years Female	DRAWN : 02/07/2024 11:36:18	
PATIENT ID : ANUDI230181707	CLIENT PATIENT ID :	RECEIVED : 02/07/2024 11:38:53	
ABHA NO :		REPORTED : 02/07/2024 18:59:03	

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM	134.5 Low	137 - 145	mmol/L
POTASSIUM, SERUM	4.17	3.6 - 5.0	mmol/L
CHLORIDE, SERUM	100.8	98 - 107	mmol/L

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, antidepressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenal insufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessive sweating, severe vomiting or diarrhea), diabetes mellitus, diabetes insipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (loss of HCO ₃ ⁻), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemia, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of

Sanjeev

Dr. Sanjeev Kumar
Consultant - Pathologist &
Laboratory Head



View Details



View Report

PERFORMED AT :

Agilus Pathlabs Reach Limited
Sadar Hospital, Sector-1, Bokoro Steel City,
Bokoro, PZ7001
Jharkhand, India
Tel : 7260813496
Email : customercare.bokoro@agilus.in



ULR No. 775000082325630

PATIENT NAME : ANU DEVI		REF. DOCTOR : DR. SADAR HOSPITAL	
ACCESSION NO : 0707XG000089	AGE/SEX : 43 Years Female	DRAWN : 02/07/2024 11:36 AM	REPORTED : 02/07/2024 11:59 AM
PATIENT ID : ANUDF230181707			
CLIENT PATIENT ID :			
ABIA NO :			

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

EIA - INFECTIOUS SECTION

HEPATITIS B SURFACE ANTIGEN, SERUM

HEPATITIS B SURFACE ANTIGEN NON REACTIVE NON REACTIVE

HEPATITIS C ANTIBODIES, SERUM

HEPATITIS - C ANTIBODIES NON REACTIVE NON REACTIVE

Interpretation(s)

HEPATITIS B SURFACE ANTIGEN, SERUM-Hepatitis B is caused by infection with HBV, a enveloped DNA agent that is classified as hepadnavirus. This test detects the presence of viral surface antigen i.e HBsAg also known as "Australia antigen" in serum sample and is indicative of HBV infection, either acute or chronic. **Test Utility:** HBsAg is the first serologic marker appearing in the serum 6-16 weeks following hepatitis B viral infection. In typical HBV infection, HBsAg will be detected 2-4 weeks before the liver enzyme levels (ALT) become abnormal and 3-5 weeks before patient develops jaundice. In acute cases HBsAg usually disappears 1-2 months after the onset of symptoms. Persistence of HBsAg for more than 6 months indicates development of either a chronic carrier state or chronic liver disease. The presence of HBsAg is frequently associated with infectivity. HBsAg when accompanied by Hepatitis Be antigen and/or hepatitis B viral DNA almost always indicates infectivity. **Limitations:** For diagnostic purposes, results should be used in conjunction with patient history and other hepatitis markers for diagnosis of acute or chronic infection. If the antibody results are inconsistent with clinical evidence, additional testing is suggested to confirm the result. HBsAg detection will only indicate the presence of surface antigens in the serum and should not be used as the sole criteria for diagnosis, staging or monitoring of HBV infection. This test may be negative during "window period" after disappearance of anti-HBsAg antibody. The current assay being a highly sensitive test may yield a small percentage of false positive reports. Hence all HBsAg positive specimens should be confirmed with an assay based upon Neutralisation of Human anti Hepatitis B Surface antibody. **HEPATITIS C ANTIBODIES, SERUM-Hepatitis C Virus (HCV)** is a blood borne flavivirus. It is one of the most important causes of post-blood transfusion as well as community acquired non-A non-B hepatitis and chronic liver failure. Although the majority of infected individuals may be asymptomatic, HCV infection may develop into chronic hepatitis, cirrhosis and/or increased risk of hepatocellular carcinoma. **Notes & Limitations:** HCV antibody is typically not detected until approximately 14 weeks after infection (or 5 weeks after appearance of the first biochemical marker of illness) and is almost always detectable by the late convalescent stage of infection. A negative result may also be observed due to loss of HCV antigen, years following resolution of infection. Infants born to hepatitis C infected mothers may have delayed seroconversion to anti-HCV. Hence a negative result should be evaluated cautiously with respect to clinical findings. It is to be noted that absence of HCV antibodies after 14 weeks of exposure is strong evidence against HCV infection. Presence of HCV antibodies does not imply an active Hepatitis C infection but is indicative of both past and/or recent infection. It has been reported that as many as 90% of individuals receiving intravenous commercial immunoglobulin test falsely positive for HCV antibody. Also, patients with autoimmune liver disease may show a false positive HCV antibody result. Hence it is advisable to confirm a positive antibody result with a supplemental test. A positive result when followed by a positive supplemental test (i.e. HCV-RNA-PCR) suggests active hepatitis C infection.

**** End Of Report ****

Please visit www.agilusdiagnostics.com for related Test Information for this accession

Sanjeew

Dr. Sanjeew Kumar
Consultant - Pathologist &
Laboratory Head



View Details



View Details

PERFORMED AT :
Agilus Pathlabs Reach Limited
Sadar Hospital, Sector-1, Bokoro Steel City,
Bokoro, 827001
Jharkhand, India
tel : 7260813496
Email : customercare_bokoro@agilus.in



ULR No. 775000008232563-0707

SADAR HOSPITAL BOKARO
CAMP 2 BOKARO



Dr. Madan Prakash

Registration No : 20230031841

Visit No : 6/ Last Visit Date : 02/04/2024 12.00 AM / Token No : 63

Room No : Main Building A, OPD Block, Ground, G. Medicine OPD 9

Medicine OPD

Name : Ms. Anu Devi

Sex/Age : 44Y 1M 17D / F

Department : Medicine

Registration Amount : Rs. 5

Mobile No : 7004608749

Address : JAINAMORE, (JHARKHAND)

Date of Registration : 02/07/2024 11.57 AM

Patient Type : General

Guardian Name : C B KUMAR (Husband)

MLC Patient : NO

Last Complete Collection Date/Amount : 14/07/2023 04.32 PM/Rs. 5

CBS-24
02/07/24

Report for Blood Exam N+
HIV - Non-Reactive

Manish
03/07/24

Prepared By: Mrs.
Preeti Kumari

Date Time: 02/07/2024 11.57 AM



PATIENT NAME : ANU DEVI

REF. DOCTOR : DR. SADAR HOSPITAL

ACCESSION NO : 0707XG000089	AGE/SEX : 43 Years Female
PATIENT ID : ANUDT230181707	DRAWN : 02/07/2024 11:36:11
CLIENT PATIENT ID :	RECEIVED : 02/07/2024 11:38:53
ADHA NO :	REPORTED : 03/07/2024 16:28:57

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

SPECIALISED CHEMISTRY - ANEMIA

SERUM IRON AND TIBC STUDIES

IRON	117	50 - 170	µg/dl
METHOD : FERENE			
TOTAL IRON BINDING CAPACITY	243 Low	250 - 450	µg/dl
METHOD : CALCULATED PARAMETER			
% SATURATION	48 High	13 - 45	%

Interpretation(s)

SERUM IRON AND TIBC STUDIES-Total iron binding capacity (TIBC) measures the blood's capacity to bind iron with transferrin and thus is an indirect way of assessing transferrin level.

Taken together with serum iron and percent transferrin saturation this test is performed when there is a concern about anemia, iron deficiency or iron deficiency anemia. However, because the liver produces transferrin, alterations in liver function (such as cirrhosis, hepatitis, or liver failure) must be considered when performing this test.

Increased in:

- iron deficiency
- acute and chronic blood loss
- acute liver damage
- progesterone birth control pills

Decreased in:

- hemochromatosis
- cirrhosis of the liver
- thalassemia
- anemias of infection and chronic diseases
- nephrosis
- hyperthyroidism

The percent transferrin saturation = Serum Iron/TIBC x 100

Unsaturated Binding Capacity (UBC)=TIBC - Serum Iron.

Limitations: Estrogens and oral contraceptives increase TIBC and Asparaginase, chloramphenicol, corticotropin, cortisone and testosterone decrease the TIBC level.

Reference:

1. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burtis, Edward R. Ashwood, David E. Bruns, 4th Edition, Elsevier publication, 2006, 563, 1314-1315.
2. Wallach's Interpretation of Diagnostic tests, 9th Edition, Ed Mary A Williamson and L Michael Snyder. Pub Uppincott Williams and Wilkins, 2011, 234-235.

****End Of Report****

Please visit www.agilusdiagnostics.com for related Test Information for this accession

Chaitali

A. Chatterjee

Page 1 of 1

Dr. Chaitali Ray, PHD
Biochemist

Dr. Anwesha Chatterjee
Pathologist



View Details

View

PERFORMED AT :

Agilus Diagnostics Ltd
P S Srijan Tech Park Building, Dn-52, Unit No. 2, Ground Floor, Sector V, Salt Lake,
Kolkata, 700091
West Bengal, India
Tel : 9111591115, Fax : 30203412
CIN - U74899PB1995PLC045956



ULR No. 77500008232563-001

OPD SLIP

मुस्कान
हॉस्पिटल
एण्ड रिसर्च सेन्टर

Dr. S. C. Munshi
MBBS, DCH, MD (Paeds)
Consultant Paediatrician &
Neonatologist
Time : 9:30 am to 01:30 pm
(Sunday Off)

Dr. Irfan Ansari
MBBS, MS (Gen. Surgery)
Consultant Laparoscopic &
Cancer Surgeon
Time : 10:30 am to 02:30 pm
(Friday Evening Off)

Dr. Md. Shahnawaj Anwar
MBBS, MD (Med.)
Consultant Physician
Cardiologist & Diabetologist
Time : 11:00 am to 02:30 pm
07:00 pm to 08:00 pm
(Sunday Evening Off)

Dr. Manoj Kr. Srivastava
MBBS, AFMC (PUNE)
Child Specialist, General
Physician & Surgeon
Time : 11:30 am to 02:00 pm

Muskan Ruganlya (P) Ltd.
Undertaking

Muskan SUPERSPECIALITY Centre

Plot No. : S-3, City Centre,
Beside M-Bazar, Sector - IV,
Bokaro Steel City (Jharkhand)
[Near Samarjit Gas Agency]
Ph. : 06542-231335, 08877080738

Facilities Available :

- # Gastroenterology Department :
 - Upper GI Endoscopy
 - Variceal Band Ligation.
 - Sclerotherapy
 - Colonoscopy
 - ERCP.
- # Eye Department :
 - Phaco Surgery & OCT etc.
 - Ben Franklin Optical Point
- # Neuro Surgery Department :
 - OPD.

Name :

Aruna Devi

Age/Sex:

43/F

Weight



MUSKAN
Hospital

& Research Centre

C 9 JUL 2024

Date :

CHEST XRAY
Thyroid workup

BP 140/70 mmHg

HR 64 bpm

SpO₂ 98%

Upper pain
Stiffness

Chest
CXR / msa

Urine next LC @
Zyg C - Skin Plw 30cm

MD Thara 1 week
Amalang 30 @
Concon 30 @
Tendyn 20 @
Shelal 10K @
Zypp 10K @
App Gust 40g 20 @

See
Amh CCP Amh body

Cafe

Report विषय का समय

1:15 PM to 1:45 PM

EXCEPT FRIDAY & SUN

8877080718, 9204061814

24 hours service available